Pipeline
Our pipeline is driven by our revolutionary research into immune response. Each product builds on our unique understanding of innate immunity and how this natural control can be used to destroy solid tumors or calm autoimmune inflammation. ASD141, our first-in-class innate immune checkpoint inhibitor, unleashes anti-tumor immunity by blocking TLT-1/CD11b signaling in the tumor microenvironment. Meanwhile, ASD001 restores immune balance in autoimmune by activating CD11b to stabilize hyperactive myeloid cells. Together, they represent a new generation of immunotherapies powered by innate immune modulation.
ASD141 – Innate ICI for immuno-oncology
ASD141 is a novel, innate immune checkpoint inhibitor (ICI) that commands the innate immune system to coordinate a renewed attack on solid tumors. As a monotherapy, ASD141 shows statistically significant inhibition of tumor growth in animal cancer models. When used in combination therapy with adaptive-immunity-targeted anti-PD1 and anti-CTLA4 ICIs, ASD141 further decreased tumor growth and increased survival rates (in animal studies).
We have received FDA clearance on first-in-human clinical trail.
ASD001 – Innate Immune Modulator for Autoimmune Diseases
ASD001 is a first-in-class monoclonal antibody targeting the innate immune checkpoint CD11b, currently in preclinical development. It rebalances overactive myeloid cells to reduce inflammation without broad immunosuppression. Initially focused on autoimmune diseases like SLE and IBD. ASD001 offers a novel mechanism for patients with limited treatment options.
Interested in being part of our journey?
We are interested in hearing from partners who are interested in co-developing or licensing ASD141 or investors who are interested in being part of this journey.
Contact our team for more information: